891 Participants Needed

Virtual Care for Heart Failure

(VICTORY-HF Trial)

Recruiting at 8 trial locations
HG
VP
Overseen ByVICTORY-HF Project office
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Population Health Research Institute
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The clinic visits (intervention) will continue for 90 days, which represents the follow-up period for the primary medication and health status outcomes. The co-primary clinical outcomes will be obtained at 180 days.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Routine HF Care, Virtual HF Care for heart failure?

Research shows that virtual healthcare solutions, including remote patient management, can significantly reduce hospital readmissions and improve self-care in heart failure patients. The TIM-HF2 trial demonstrated that remote patient management reduced all-cause mortality and hospitalizations compared to usual care.12345

Is virtual care for heart failure safe for humans?

The research on virtual care for heart failure, which includes remote monitoring and digital health solutions, does not specifically mention safety concerns, suggesting it is generally considered safe for human use.46789

How does the Virtual HF Care treatment differ from other heart failure treatments?

Virtual HF Care is unique because it uses mobile technologies and virtual visits to provide remote monitoring and real-time communication between patients and healthcare providers, which can help reduce hospital readmissions and improve patient self-care. This approach is particularly beneficial for older, frail, or homebound patients who face challenges accessing traditional in-person care.234710

Research Team

HV

Harriette Van Spall, MD

Principal Investigator

McMaster University

Eligibility Criteria

This trial is for adults over 18 with heart failure, recently hospitalized or seen urgently for the condition. Participants must have NT-proBNP >900 pg/ml and LVEF <55% within the last 3 months. They should be able to use virtual care tools (with help if needed) and provide a mailing address.

Inclusion Criteria

provide consent.
have a mailing address for the patient or caregiver
are competent (either independently or with caregiver) in using the virtual care platform during a brief demonstration
See 3 more

Timeline

Pilot Phase

Pilot phase conducted to assess the acceptability and feasibility of the intervention, refine the virtual delivery process, and finalize protocols

Not specified

Treatment

Participants receive virtual HF care to optimize medical therapies

90 days
Number of virtual and in-person clinic visits per patient in 90 days

Follow-up

Participants are monitored for primary medication and health status outcomes

90 days

Extended Follow-up

Co-primary clinical outcomes obtained, including all-cause death, HF hospitalization, and ED visits

180 days

Treatment Details

Interventions

  • Routine HF Care
  • Virtual HF Care
Trial OverviewThe study compares two types of post-hospitalization heart failure care: Virtual HF Care versus Routine HF Care. It examines how these approaches affect medication adherence and health status over a follow-up period of 90 days, with clinical outcomes assessed at 180 days.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Virtual HF careExperimental Treatment1 Intervention
Patients will receive virtual HF care to optimize medical therapies
Group II: Routine HF careExperimental Treatment1 Intervention
Participants will receive routine HF care

Find a Clinic Near You

Who Is Running the Clinical Trial?

Population Health Research Institute

Lead Sponsor

Trials
165
Recruited
717,000+

Hamilton Health Sciences Corporation

Collaborator

Trials
380
Recruited
345,000+

McMaster University

Collaborator

Trials
936
Recruited
2,630,000+

Findings from Research

In the TIM-HF2 trial involving 1,538 heart failure patients, remote patient management (RPM) showed a significant reduction in all-cause mortality for patients with an estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 m², with a 1-year survival rate of 89.4% compared to 84.6% in usual care (UC).
RPM also led to lower rates of heart failure hospitalizations and all-cause death in both eGFR subgroups, indicating its potential effectiveness in managing heart failure, particularly in patients with compromised kidney function.
Remote Patient Management May Reduce All-Cause Mortality in Patients With Heart-Failure and Renal Impairment.Naik, MG., Budde, K., Koehler, K., et al.[2022]
A study involving 49 homebound, frail, and older patients with heart failure showed that nurse-assisted virtual video visits significantly reduced hospitalization rates and days compared to the previous year, indicating improved management of heart failure in this population.
The model demonstrated a decrease in emergency department visits, suggesting that virtual care can effectively address the barriers faced by older patients in accessing specialized cardiac care.
Management of Frail and Older Homebound Patients With Heart Failure: A Contemporary Virtual Ambulatory Model.Kobulnik, J., Wang, IY., Bell, C., et al.[2022]
The LEAP Virtual Visit protocol for heart failure patients outlines a structured approach to virtual healthcare, detailing specific steps, roles, and tools needed for effective implementation, which can enhance patient care.
This protocol includes comprehensive support materials for both clinicians and patients, aiming to improve satisfaction and streamline the virtual visit process, potentially benefiting the overall healthcare system.
LEAP Virtual Visit Assessment (VIVA): a structured protocol for virtual visits for patients with heart failure.Gori, M., Bonmassari, R., Correale, M., et al.[2022]

References

Remote Patient Management May Reduce All-Cause Mortality in Patients With Heart-Failure and Renal Impairment. [2022]
Management of Frail and Older Homebound Patients With Heart Failure: A Contemporary Virtual Ambulatory Model. [2022]
LEAP Virtual Visit Assessment (VIVA): a structured protocol for virtual visits for patients with heart failure. [2022]
Virtual healthcare solutions in heart failure: a literature review. [2023]
Effects of remote patient management on self-care behaviour in heart failure patients: results from the randomized TIM-HF2 trial. [2023]
Improving outpatient care for heart failure through digital innovation: a feasibility study. [2022]
Evaluating a Web-Based Self-Management Intervention in Heart Failure Patients: A Pilot Study. [2020]
Patients' preferences regarding the digital capturing of patient-reported outcomes: planning the future follow-up in a prospective heart failure registry. [2023]
Digital health intervention in patients with recent hospitalization for acute heart failure: A systematic review and meta-analysis of randomized trials. [2022]
Artificial intelligence supported patient self-care in chronic heart failure: a paradigm shift from reactive to predictive, preventive and personalised care. [2020]